While its effective for headaches, muscle aches, and fever, its not without risks when combined with other substances
doi: 10.1097/sla.0000000000005591 9 TrevesN
Tesamorelin operates through an entirely different pathway
Phase 2 Trial (published in NEJM, June 2023): 48-week randomised controlled trial 338 adults with obesity or overweight, without type 2 diabetes Tested against placebo At the 12mg dose, participants lost an average of 24.2% of their body weight over 48 weeks
Additionally, we considered that as the manufacturing process is scaled up, other formulation or manufacturing changes are made, and new breakthroughs are made in biologic drug production the manufacturing cost might change significantly
Obesity is a chronic condition that needs long-term management